Weiqing Wang
Memorial Sloan Kettering Cancer Center
16 Papers
67 Citations
Weiqing Wang is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 9, co-authored 12 publications. Previous affiliations of Weiqing Wang include Kettering University.
Chat about Author
Papers
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph,Christine A. Pratilas,Poulikos I. Poulikakos,Madhavi Tadi,Weiqing Wang,Barry S. Taylor,Ensar Halilovic,Ensar Halilovic,Yogindra Persaud,Feng Xing,Agnes Viale,James Tsai,Paul B. Chapman,Gideon Bollag,David B. Solit,Neal Rosen +15 more
TL;DR: The data explain why the drug selectively inhibits the growth of mutant BRAF tumors and suggest that it will not cause toxicity resulting from the inhibition of ERK signaling in normal cells, and help explain the greater antitumor activity observed with this drug than with MEK inhibitors.
483
Models from experiments: combinatorial drug perturbations of cancer cells
Sven Nelander,Weiqing Wang,Bjoern Nilsson,Qing-Bai She,Christine A. Pratilas,Neal Rosen,Peter Gennemark,Chris Sander +7 more
TL;DR: A novel method for deriving network models from molecular profiles of perturbed cellular systems, capable of representing epistasis and saturation effects, and the discovery of regulatory interactions, the design of targeted combination therapies and the engineering of molecular biological networks is presented.
Perturbation Biology: Inferring Signaling Networks in Cellular Systems
Evan J Molinelli,Evan J Molinelli,Anil Korkut,Weiqing Wang,Martin L. Miller,Nicholas P. Gauthier,Xiaohong Jing,Poorvi Kaushik,Poorvi Kaushik,Qin He,Gordon B. Mills,David B. Solit,Christine A. Pratilas,Martin Weigt,Alfredo Braunstein,Andrea Pagnani,Riccardo Zecchina,Chris Sander +17 more
TL;DR: A powerful experimental-computational technology for inferring network models that predict the response of cells to perturbations, and that may be useful in the design of combinatorial therapy against cancer, is presented.
Off-target effects dominate a large-scale RNAi screen for modulators of the TGF-β pathway and reveal microRNA regulation of TGFBR2
Nikolaus Schultz,Dina R Marenstein,Dino A. De Angelis,Weiqing Wang,Sven Nelander,Sven Nelander,Anders Jacobsen,Debora S. Marks,Joan Massagué,Chris Sander +9 more
TL;DR: It is suggested that the type II TGF-β receptor is regulated by multiple miRNAs, and the risk of obtaining misleading results in siRNA screens using large libraries with single-assay readout is substantial.
Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles
Bulent Arman Aksoy,Emek Demir,Özgün Babur,Weiqing Wang,Xiaohong Jing,Nikolaus Schultz,Chris Sander +6 more
TL;DR: Genetic profiling will in the future provide a promising basis for network pharmacology of epistatic vulnerabilities as a promising therapeutic strategy in cancer, and up to 44% of vulnerabilities can be targeted with at least one Food and Drug Administration-approved drug.